Psilocybin reduces symptoms in treatment resistant depression, trial results show
British medical journal November 2, 2022 DOI: 10.1136/bmj.o2623 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Randomized controlled trial Peer reviewed |
|---|---|
| Sample size | 233 |
| Population | Patients with treatment resistant depression |
| Intervention | Psilocybin |
| Dose | 25 mg, 10 mg, or 1 mg (control) |
| Duration | 12 weeks |
| Topics | Depression Psilocybin |
| Citations | 5 |
| Key findings | A single 25 mg dose of psilocybin reduced depression scores more than a 1 mg control dose over 12 weeks in patients with treatment-resistant depression. |
Abstract
single a Researchers investigated the effects of single doses of 25 mg, 10 mg, or 1 mg (control) psilocybin over 12 weeks in 233 patients with treatment resistant depression. They were given the treatment in specialised rooms designed to provide a non-clinical and calming atmosphere where a specially trained therapist was available to provide psychological support. The psychedelic effects of psilocybin last as long as eight hours, and once these had passed the participants were able to return home.